贝伐珠单抗治疗脑胶质瘤的研究进展  

Research Progress of Bevacizumab in the Treatment of Glioma

作　　者：魏梦凡 王艳婷 赵红[1] 

机构地区：[1]延安大学附属医院肿瘤科,陕西 延安

出　　处：《临床医学进展》2023年第8期12277-12283,共7页Advances in Clinical Medicine

摘　　要：脑胶质瘤是成人最常见的原发性脑肿瘤,也是肿瘤中预后最差的肿瘤之一。目前的常规治疗方法以手术切除为主,术后放疗联合替莫唑胺(temozolomide, TMZ)同步并辅助TMZ化疗。虽然近年来脑胶质瘤的治疗方法在电场疗法、免疫治疗、靶向治疗、硼中子俘获治疗等疗法都有了新的突破,但是患者的生存期对比于其他肿瘤还是处于较低水平。2009年贝伐珠单抗(bevacizumab, Bev)在美国被批准用于复发性胶质母细胞瘤(GBM),这给患者提供了一个新的选择。本文将总结Bev治疗脑胶质瘤的研究进展以及其应用中存在的一些问题。Glioma is the most common primary brain tumor in adults and one of the tumors with the worst prognosis. Current conventional treatment is mainly surgical resection, with postoperative radio-therapy combined with temozolomide (TMZ) synchronized and adjuvant TMZ chemotherapy. Alt-hough the treatment methods of glioma have made new breakthroughs in electric field therapy, immunotherapy, targeted therapy, boron neutron capture therapy and other therapies in recent years, the survival time of patients is still at a low level compared with other tumors. Bevacizumab (BEV) was approved in the United States in 2009 for recurrent glioblastoma (GBM), which gave pa-tients a new option. This article will summarize the research progress of Bev in the treatment of glioma and some problems in its application.

关 键 词：脑胶质瘤 贝伐珠单抗 替莫唑胺 

分 类 号：R73[医药卫生—肿瘤]